<div><h3>Background</h3><p>Liraglutide is a glucagon-like peptide-1 analogue that stimulates insulin secretion and improves β-cell function. However, it is not clear whether liraglutide achieves its glucose lowering effect only by its known effects or whether other as yet unknown mechanisms are involved. The aim of this study was to examine the effects of liraglutide on Fibroblast growth factor-21 (FGF-21) activity in High-fat diet (HFD) fed ApoE<sup>−/−</sup> mice with adiponectin (Acrp30) knockdown.</p> <h3>Method</h3><p>HFD-fed ApoE<b><sup>−/−</sup></b> mice were treated with adenovirus vectors expressing <em>shAcrp30</em> to produce insulin resistance. Hyperinsulinemic-euglycemic clamp studies were performed to evaluate insulin sensitiv...
Background & AimsInsulin resistance and lipotoxicity are pathognomonic in non-alcoholic steatohepati...
ObjectiveThe efficacy of liraglutide, a human glucagon-like peptide-1 (GLP-1) analog, to prevent or ...
International audienceObjectiveTreatment with liraglutide, a GLP-1 (glucagon-like peptide-1) agonist...
Background: Liraglutide is a glucagon-like peptide-1 analogue that stimulates insulin secretion and ...
mice with adiponectin (Acrp30) knockdown. to produce insulin resistance. Hyperinsulinemic-euglycemi...
mice with adiponectin (Acrp30) knockdown. to produce insulin resistance. Hyperinsulinemic-euglycemi...
Social isolation contributes to the development of obesity and insulin-independent diabetes in KKAy ...
The incretin effect is essential for glucose homeostasis. Glucagon-like peptide 1 (GLP-1) based drug...
<p>(A) body weights during liraglutide treatment (n = 6–7). Open circles, liraglutide-treated <i>Gcg...
Aims. Glucagon-like peptide-1 (GLP-1) analog promotes insulin secretion by acting on pancreatic β-ce...
Liraglutide, a glucagon-like peptide-1 analog, has been proved to reduce body weight and visceral ad...
Insulin resistance and lipotoxicity are pathognomonic in non-alcoholic steatohepatitis (NASH). Gluca...
Insulin resistance and lipotoxicity are pathognomonic in non-alcoholic steatohepatitis (NASH). Gluca...
ObjectiveThe efficacy of liraglutide, a human glucagon-like peptide-1 (GLP-1) analog, to prevent or ...
Abstract Background Proprotein convertase subtilisin/kexin type 9 (PCSK9), a major regulator of chol...
Background & AimsInsulin resistance and lipotoxicity are pathognomonic in non-alcoholic steatohepati...
ObjectiveThe efficacy of liraglutide, a human glucagon-like peptide-1 (GLP-1) analog, to prevent or ...
International audienceObjectiveTreatment with liraglutide, a GLP-1 (glucagon-like peptide-1) agonist...
Background: Liraglutide is a glucagon-like peptide-1 analogue that stimulates insulin secretion and ...
mice with adiponectin (Acrp30) knockdown. to produce insulin resistance. Hyperinsulinemic-euglycemi...
mice with adiponectin (Acrp30) knockdown. to produce insulin resistance. Hyperinsulinemic-euglycemi...
Social isolation contributes to the development of obesity and insulin-independent diabetes in KKAy ...
The incretin effect is essential for glucose homeostasis. Glucagon-like peptide 1 (GLP-1) based drug...
<p>(A) body weights during liraglutide treatment (n = 6–7). Open circles, liraglutide-treated <i>Gcg...
Aims. Glucagon-like peptide-1 (GLP-1) analog promotes insulin secretion by acting on pancreatic β-ce...
Liraglutide, a glucagon-like peptide-1 analog, has been proved to reduce body weight and visceral ad...
Insulin resistance and lipotoxicity are pathognomonic in non-alcoholic steatohepatitis (NASH). Gluca...
Insulin resistance and lipotoxicity are pathognomonic in non-alcoholic steatohepatitis (NASH). Gluca...
ObjectiveThe efficacy of liraglutide, a human glucagon-like peptide-1 (GLP-1) analog, to prevent or ...
Abstract Background Proprotein convertase subtilisin/kexin type 9 (PCSK9), a major regulator of chol...
Background & AimsInsulin resistance and lipotoxicity are pathognomonic in non-alcoholic steatohepati...
ObjectiveThe efficacy of liraglutide, a human glucagon-like peptide-1 (GLP-1) analog, to prevent or ...
International audienceObjectiveTreatment with liraglutide, a GLP-1 (glucagon-like peptide-1) agonist...